Nonetheless, a subsequent study indicated that the 1p/19q co-deletion in glioma can trigger a reduction in TIM-3 (and galectin-9) expression leading to enhanced antitumor activity, and thus providing a potential mechanism for why patients with this co-deletion may have enhanced survival [86]. The gene discussed is HAVCR2; the disease is central nervous system cancer.